中文网站正在持续更新中,请密切关注我们康肽生物的最新动态,或点击访问右上角的英文官方网站 www.phoenixpeptide.com
PHOENIX PHARMACEUTICALS, INC. TOP HOME PAGE
Top Catalog English Version | My Account | 联系我们 | China



 多肽



 标记多肽 



 多肽激素文库



 抗体 



 免疫试剂盒 



 生物标志物阵列 



 多肽样品检测



 自定义肽链合成及GMP



 产品目录索取



 样品准备



 提问和解答


Normal Human Plasma Peptide or Protein Levels (updated on 08/08/2012)

Peptide  
Normal Subjects  
Reference
ACTH  200-250 pg/ml  Jansson et al. Clin Endocrinol (Oxf) 1998 Feb;48(2):243-50
Adiponectin (plasma)  8.7~10.4 µg/ml (n=6)  Phoenix Pharmaceuticals
Adiponectin (serum samples)  11.82 ± 0.97 µg/ml [normal glucose tolerance (NGT)]  Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9.
Adiponectin (serum samples)  9.11 ± 1.12 µg/ml [impaired glucose tolerance(IGT)]  Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9.
Adiponectin (serum samples)  7.44 ± 1.53 µg/ml [diabetes (DM)]  Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9.
Adrenomedullin (AM)  2.94 ± 0.15 fmol/mL; n = 16  Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3.
Adrenomedullin (AM)  8.74 ± 0.44 fmol/mL; n = 16; class I or II of the New York Heart Association functional classification  Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3.
Adrenomedullin (AM)  11.82 ± 1.81 fmol/mL; n = 5; class III or IV of the New York Heart Association functional classification  Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3.
Adrenomedullin (ADM)  6.14  ±0.25 pmol/L  Kato et al. Hypertens Res. 1999 Mar;22(1):61-5.
Adrenomedullin (ADM)  480 ± 135 pg/ ml  Pousset et al. Eur Heart J 2000 Jun;21(12):1009-14
mADM (amidated mature form)  0.5 ±0.1 fmol/ml  Ishihara et al.Clin Nephrol 1999 Aug;52(2):119-23
Intermedin/AM-2  50-120 pg/ml  Phoenix Pharmaceuticals
Intermedin/AM-2, prepro (25-56) (Human)  173 pg/ml  Phoenix Pharmaceuticals
Amylin  8.48±3.12 pmol/L (total plasma levels)  Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7.
Amylin  6.29±1.47 pmol/l (patients with type 2 diabetes)  Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7.
Amylin  3.33±0.46 pmol/l (patients with osteoporosis)  Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7.
ANP (Fetal blood samples)  ANP: 80.8±16.6 vs. 31.6±7.7 pg/ml  Walther et al. Cardiovasc Res. 2001 Mar;49(4):817-9
ANP  24 fmol/ml  Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6.
ANP  73 pg/ml  McDowell et al. Br J Clin Pharmacol 1997 Mar;43(3):329-32
ANP  27 ± 5 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
ANP (chronic cardiac failure)  136 ± 35 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
NT-proANP  1130 ±170 pmol/l  Uusimaa et al. Int J Cardiol 1999 Apr 30;69(1):5-14
Angiotensin II   21 ±4 pg/ml  Gustafsson et al. Blood Press 1992 May;1(1):50-6
Apelin (apelin-12)  175 pg/ml (by RIA)  Boucher et al. Endocrinology. 2005 Apr;146(4):1764-71.
Apelin (apelin-12)  275 pg/ml (obesity)  Boucher et al. Endocrinology. 2005 Apr;146(4):1764-71.
Apelin (apelin-36)  174±14 pg/ml  Heinonen et al. Regul Pept. 2005 Aug 15;130(1-2):7-13
Apelin (apelin-36)  736 ± 50 pg/ml (obesity)  Heinonen et al. Regul Pept. 2005 Aug 15;130(1-2):7-13
Arg8-Vasopressin (AVP)  0.9 ±0.2 pg/ml  Pump et al. Am J Physiol 1999 Jul;277(1 Pt 2):R229-35
BNP (Fetal blood samples)  64.8+/-6.6 pg/ml  Walther et al. Cardiovasc Res. 2001 Mar;49(4):817-9
BNP  17.5 ±1.6 pmol/L  Sayama et al. Coron Artery Dis 1999 Oct;10(7):537-40
BNP  13.3 ±2.7 pg/ml  Bando et al. Respir Med 1999 Jul;93(7):507-14
BNP32  9.7 ±0.5 pmol/L  Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96
BNP32  29 ±2 pmol/L (NYHA Classes I, II and III )  Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96
NT-proBNP  1.5  (1.0 ~ 13.8) fmol/mL (women)  Campbell et al. J Card Fail 2000 Jun;6(2):130-9
NT-proBNP  1.0 (1.0 ~ 3.3) fmol/mL (men)  Campbell et al. J Card Fail 2000 Jun;6(2):130-9
NT-proBNP  10.8 ± 1.3 pmol/L  Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96
NT-proBNP  129 ± 12 pmol/L (NYHA Classes I, II and III )  Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96
Bradykinin  2.6 fmol/ml  Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6.
Cholecystokinin (CCK)  8.0 ± 6.3 pmol/l (control group)  Foschi et al. Obes Surg. 2004 May;14(5):644-7
Cholecystokinin (CCK)  9.8 ±6.7 pmol/l [obese patients before vertical banded gastroplasty (VBG)]  Foschi et al. Obes Surg. 2004 May;14(5):644-7
Cholecystokinin (CCK)  24.9 ±18 pmol/l [obese patients before vertical banded gastroplasty (VBG)]  Foschi et al. Obes Surg. 2004 May;14(5):644-7
CGRP  13.9 (10.9-36.96) pmol/L  Onuoha et al. Life Sci 1999;65(13): 1351-8
CGRP  34 pg/ml  McDowell et al. Br J Clin Pharmacol 1997 Mar;43(3):329-32
CGRP (external jugular vein blood levels)  110 ±7 pmol/L (attacks of cluster headache)  Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34
CGRP (external jugular vein blood levels)  less than 7 pmol/L (normal control)  Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34
Calcitonin  6.9 pmol/L  Henriksen et al. Metabolism 2000 Jan;49(1):47-52
Calcitonin  < 10 pg/mL  Cohen et al. J Clin Endocrinol Metab 2000 Feb;85(2):919-22
CNP-22 (Human)  11.64 ±4.32 pg/ml  Stepan et al. J Perinat Med 2000;28(2):118-21
CNP  7.1 ±2.5 pg ml (women with normal pregnancy)  Stepan et al. Obstet Gynecol 1999; 93(2):199-202
CNP  7.36 ±3.0 pg/ml (Maternal Plasma in health pregnancy women in the third trimenon)  Stepan et al. J Perinat Med 1998; 26(5):396-9
CRF  1.64 ±0.43 pmol/L( 0.77-2.5 pmol/L).  Hashimoto et al. Acta Endocrinol (Copenh) 1993 Jun;128(6):503-7
pro-alpha-C-related immunoreactive peptides (pro-alpha-C-RI) (serum)  402 ±38 pg/mL  Anawalt et al. J Clin Endocrinol Metab. 1996 Sep;81(9):3341-5.
DNP  105.3 ±31.1 pg/mL  Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5
DNP  235.6 ±45.8 pg/mL (pre-haemodialysis)  Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5
DNP  204.4 ±55.4 pg/mL (after haemodialysis )  Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5
Endothelin  8.8 (1.7-32.9) pmol/L  Onuoha et al. Life Sci 1999;65(13): 1351-8
Endorphin, Beta-,  30 ±5 pg/ml  Laurent et al. J Clin Endocrinol Metab. 2000 Jun;85(6):2170-5.
Endorphin, Beta-,  18.9 ±5.4 pg/ ml (range 2.0 to 29.6 pg/ml), before treatment  El-Sheikh et al. Pain Physician. 2004 Jan;7(1):67-70
Endorphin, Beta-,  38.7 ±17.6 pg/ml (range 13.2 to 67.9 pg/ml), after pain relief  El-Sheikh et al. Pain Physician. 2004 Jan;7(1):67-70
Gastrin  7.8 ±1.6 pg/ml (before lunch)  Takeyama et al. Chem Pharm Bull (Tokyo) 1993; 41(12):2197-9
Gastrin  26.4 ±8.4 pg/ml (after lunch)  Takeyama et al. Chem Pharm Bull (Tokyo) 1993; 41(12):2197-9
Gastrin I  52.80 ±13.37 pg/ml (maternal blood)  Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8
Gastrin I  84.12 ±42.90 pg/ml (cord blood)  Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8
Gastrin I  32.34 ±18.35 pg/ml (plasma in healthy,nonpregnant women)  Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8
Gastrin-relasing peptide (GRP)  40 ± 4 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
Gastrin-relasing peptide (GRP) [(chronic cardiac failure)]  29 ± 4 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
GH  29.9±23.1 ng/ml  Takeno et al. Eur J Endocrinol. 2004 Oct;151(4):447-50
Ghrelin (Human)  87.79 ±10.27 pg/ml  Dr. C Y  Bowers, School of Medicine, Tulane University Medical Center
GHRH (children with short stature)  51 ± 10 pg/ml  Brion et al. Horm Res. 1986;24(2-3):116-20.
GHRH (children with short stature)  24.6 ± 4.9 pg/ml  Rosskamp et al. Klin Wochenschr. 1988 Mar 15;66(6):257-60.
GHRH (children with Type 1 diabetes)  27.0 ± 3.9 pg/ml  Rosskamp et al. Klin Wochenschr. 1988 Mar 15;66(6):257-60.
GIP  42 ±18 pmol/L  Kruszynska et al. Hepatology 1995 Apr;21(4):933-41
Glucagon  57 ± 3 pg/ml (ng/L)  Blümer et al. Metabolism. 2005 Jan;54(1):60-6.
GLP-1 [7-36 amide]   16 ±1 pmol/L  Kruszynska et al. Hepatology 1995 Apr;21(4):933-41
GLP-1  0.25 pmol/L  Gutzwiller et al. Am J Physiol 1999 May;276(5 Pt 2):R1541-4
GLP-2  851 ±230 pg/ml  Brubaker et al. Endocrinology. 1997 Nov;138(11):4837-43.
Insulin  36 ± 3 pmol/L  Blümer et al. Metabolism. 2005 Jan;54(1):60-6.
INSL3 (serum)  758.42±83.21 pg/ml (male)  Phoenix Pharmaceuticals
INSL3 (serum)  59.42 ±25.76 pg/ml (female)  Phoenix Pharmaceuticals
INSL3 (serum)  566.3±163.5 pg/mL (male)  Foresta et al. J Clin Endocrinol Metab. 2004 Dec;89(12):5952-8
INSL3 (plasma)  594.10±118.7 pg/ml (male)  Phoenix Pharmaceuticals
INSL3 (plasma)  47.13±19.84 pg/ml (female)  Phoenix Pharmaceuticals
LL37  50-80 ng/ml  Phoenix Pharmaceuticals
Leu-enkephalin  5.22 ±1.53 pmol/ml  Klin et al. Boll Chim Farm 1998 Sep;137(8):306-13
MCH  1.5 ng/ml  Phoenix Pharmaceuticals
Motilin [migrating motor complex (MMC)]  39 ± 6 pmol L-1  Naslund E, et al. Acta Physiol Scand. 1998 Nov;164(3):317-23
Motilin  64.1±30.1 pmol/L (healthy infants)  Savino et al. Acta Paediatr. 2006 Jun;95(6):738-41
NPY  89.22 pg/ml  Liu et al. Zhonghua Nei Ke Za Zhi. 1994 Oct;33(10):687-9.
NPY  70.7  ± 5.9 pg/ml  Kokot et al. Am J Nephrol 1999;19(1):28-33
NPY  11 (10.3-12.8) pmol/L  Onuoha et al. Life Sci 1999;65(13): 1351-8
NPY  2.5 pmol/L  Saelsen et al. Scand J Clin Lab Invest 1994 May;54(3):207-14
NPY  10.91 ±0.68 ng/ml  Kokot et al. Arch Immunol Ther Exp (Warsz) 1998;46(5):311-6
OFQ/nociceptin  9.58 ± 2.57 pg/ml  Ertsey et al. Cephalalgia. 2004 Apr;24(4):280-3
OFQ/nociceptin  4.91 ± 1.96 pg/ml ( cluster headache patients)  Ertsey et al. Cephalalgia. 2004 Apr;24(4):280-3
Orexin A  20.6 ± 4.5 pg/ml  Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9
Orexin A (obstructive sleep apnea syndrome)  9.4 ± 1.9 pg/ml  Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9
Orexin A (treated patients with OSAS)  4.2 ± 1.5 pg/ml  Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9
Oxytocin  1.3 ± 0.1 pmol/L (MW 1009.22)  Ohlsson et al. BMC Gastroenterol. 2004 Oct 7;4:25.
Oxytocin  1.66 ± 0.10 pmol/L (1.67+-0.10 pg/ml) [Early follicular]  Altemus et al. J Clin Endocrinol Metab. 2001 Jun;86(6):2525-30.
Oxytocin  1.95 ± 0.45 pmol/L (1.96 ± 0.45 pg/ml) [Midluteal]  Altemus et al. J Clin Endocrinol Metab. 2001 Jun;86(6):2525-30.
Oxytocin  [corpus cavernosum]66.7±34 to 75±44 pg/ml  Uckert et al. World J Urol. 2003 May;20(6):323-6.
Oxytocin  [cubital vein] 71±41 to 79±49.5 pg/ml  Uckert et al. World J Urol. 2003 May;20(6):323-6.
Pancreatic Polypeptide  218 ±23 pg/ml (healthy subjects)  Glaser et al. Horm Metab res 1988; 20(5):288-92
Pancreatic Polypeptide  98 ±13 pg/ml (Obese with normal glucose tolerance)  Glaser et al. Horm Metab res 1988; 20(5):288-92
Pancreatic Polypeptide  578 ±115 pg/ml (Obese with abnormal glucose tolerance)  Glaser et al. Horm Metab res 1988; 20(5):288-92
PYY (fasting levels)  10.2±0.7 pmol/L (obese group)  (Dr. Bloom's Lab) Batterham et al. N Engl J Med. 2003 Sep 4;349(10) : 941-8.
PYY (fasting levels)  16.9±0.8 pmol/L (lean group)  (Dr. Bloom's Lab) Batterham et al. N Engl J Med. 2003 Sep 4;349(10) : 941-8.
RBP-4  25.0 ± 8.9 mg/ml (n=10)  Tan et al. J Clin Endocrinol Metab. 2007 Jul;92(7):2764-72.
RBP-4 (PCOS)  35.0 ± 7.6 mg/ml (n=10)  Tan et al. J Clin Endocrinol Metab. 2007 Jul;92(7):2764-72.
Resistin  18.9 ± 3.4 ng/ml  Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10.
Resistin (T2DM)  22.6 ± 4.5 ng/ml  Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10.
Resistin (CHD)  24.2 ± 3.2 ng/ml  Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10.
Secretin  6.7 ±0.5 pg/ml (fasting plasma)  Rominger et al. Dig Dis Sci 1981; 26(7):591-7
Secretin  10.2 ±1.2 pg/ml (fasting plasma in duodenal ulcer )  Rominger et al. Dig Dis Sci 1981; 26(7):591-7
Secretin  32 ±4 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
Secretin [(chronic cardiac failure)]  13± 1 ng/L (pg/ml)  Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404
Somatostatin  13.3 +/- 5.3 pg/ml Saito H, Saito S.Horm Metab Res. 1982 Feb;14(2):71-6.
Substance P  <10 pg/mL  Vinik et al. J Clin Endocrinol Metab. 1990 Jun;70(6):1702-9
Substance P  50 pg/mL as the cutoff point, the sensitivity was 63% for detection of a tumor, and 100% of nontumor patients were excluded  Vinik et al. J Clin Endocrinol Metab. 1990 Jun;70(6):1702-9
Substance P  5.6 (3.2-36.6) pmol/L  Onuoha et al. Life Sci 1999;65(13): 1351-8
Substance P [ [[migrating motor complex (MMC)]  718 ± 326 pmol L-1  Naslund et al. Acta Physiol Scand. 1998 Nov;164(3):317-23
TNF-alpha  21 pg/ml  Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6.
TNF-alpha  1.4  ± 0.3 pg/ml  Blümer et al. Metabolism. 2005 Jan;54(1):60-6.
VIP  9.8 pmol/L (0-34)  Onuoha et al. Eur J Clin Invest. 2000 Jul;30(7):570-7
VIP [[migrating motor complex (MMC)]]  79 ± 23 pmol L-1  Naslund et al. Acta Physiol Scand. 1998 Nov;164(3):317-23
VIP  42.44 ± 2.540 pg/ml (range, 12.9-98.5 pg/ml) (serum)  Hejna et al. Anticancer Res 2001 Mar-Apr;21(2A):1183-7
VIP (external jugular vein blood)  20 ± 3 pmol/L (attacks of cluster headache, normal less than 7 )  Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34
VIP (by EIA)  307.1±42.6 µg/ml  Umemoto et al. J Dermatol Sci. 2003 Apr;31(2):161-4
Urotensin II (Human)  5.5 ±0.2 pg/ml  (extracted plasma)  Dr. Chao-Shu Tang, 1st Hospital, Peking University, P.R.China
Urotensin II (Human)  45.5 ±3.1 pg/ml (non-extracted plasma)  Dr. Chao-Shu Tang, 1st Hospital, Peking University, P.R.China
Urotensin II (Human)  7.70 ±0.97 pg/ml (extracted plasma)  Phoenix Pharmaceuticals
Urotensin II (Human)  19.0 pg/mL [10.6-24.9 pg/mL] [CSF from patients with essential hypertension]  Thompson et al. Anesth Analg. 2003 Nov;97(5):1501-3
Urotensin II (Human)  722.3 pg/mL [17.7-28.4 pg/mL] [CSF from patients with essential hypertension]  Thompson et al. Anesth Analg. 2003 Nov;97(5):1501-3
Urotensin II (Human)  22.7 ± 6.1 pg/ml, n = 18, [sample from aortic root of patients with nonfailing hearts]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  38.2 ± 6.1 pg/ml, n = 21, [sample from pulmonary artery of patients with nonfailing hearts]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  230.9 ± 68.7 pg/ml, n = 21, [[sample from aortic root of CHF patients]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  142.1 ± 51.5 pg/ml, n = 10,  [sample from aortic root of CHF patients with nonischemic cardiomyopathy]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  27.3 ± 12.4 pg/ml, n = 7 [sample from aortic root of patients with nonfailing hearts without coronary artery disease]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  311.6 ± 120.4 pg/ml, n = 11, [sample from aortic root of CHF patients with ischemic cardiomyopathy]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  19.8 ± 6.6 pg/ml, n = 11, [sample from aortic root of patients with nonfailing hearts and coronary artery disease]  Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81
Urotensin II (Human)  4.4 ±0.2 fmol/ml, n=10, [non-proteinuric diabetic patients]  Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5
Urotensin II (Human)  7.8 ± 0.6 fmol/ml, n=6, [proteinuric diabetic patients]  Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5
Urotensin II (Human)  7.3 ± 0.9 fmol/ml, n=22, [normal subjects]  Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5
Urotensin II (Human)  8.8 ± 0.9 pmol/l [62 normotensive controls (45% male, aged 54 ± 13 years)]  Cheung et al. J Hypertens. 2004 Jul;22(7):1341-4
Urotensin II (Human)  13.6 ± 1.4 pmol/l [Sixty-two hypertensive outpatient subjects (52% male, aged 57 ± 13 years)]  Cheung et al. J Hypertens. 2004 Jul;22(7):1341-4
Urotensin II (Human)  3.70 ± 1.30 pg/ml  Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5
Urotensin II (Human)  1.61 ± 1.02 pg/ml [Venous plasma, CHD patients ]  Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5
Urotensin II (Human)  patients with stable angina (2.62±1.20 pg/ml), unstable angina (1.39±0.80 pg/ml) and acute myocardial infarction (AMI, 1.04±0.45 pg/ml, P=0.004)  Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5
Urotensin II (Human)  patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) had higher U II levels than the other subjects in the CHD patient group (2.28±0.94 pg/ml vs 1.40±0.96 pg/ml, P=0.008), and the femoral plasma U II levels were significantly elevated after PTCT, increasing from 1.18±1.14 pg/ml to a postoperative level of 2.22±1.77 pg/ml (P=0.001).  Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5
Urotensin II (Human)  patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) had higher U II levels than the other subjects in the CHD patient group (2.28±0.94 pg/ml vs 1.40±0.96 pg/ml, P=0.008), and the femoral plasma U II levels were significantly elevated after PTCT, increasing from 1.18±1.14 pg/ml to a postoperative level of 2.22±1.77 pg/ml (P=0.001).  Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5
Visfatin (obese subjects) 37 ± 1 ng/ml  Haider et al. J Clin Endocrinol Metab, 2006, 91(4): 1578-1581

Coversion FAQs

How to calculate from pg/tube to pg/ml?

tube= 100 ul of standard solution or sample

Y pg/tube = 10 x Y pg/ml

How to calculate from pg/tube to pmol/L?
In short form:

How to calculate from pg/ml to pmol/L?

Y pg/ml x [1000/MW] = [ Y x 1000] / MW pmol/L ( fmol/ml)

The molecular weight can be found on each individual product page under the "Peptides" section.
If you diluted your samples before the assay, please remember to include these in your calculations.

%acth%;%adiponectin%;%adrenomedullin%;%intermedin%;%amylin%;%anp%;%angiotensin%;%apelin%;%avp%;%bnp%;%bradykinin%;%cck%;%cgrp%;%calcitonin%;%cnp%;%dnp%;%endothelin%;%betaendorphin%;%gastrin%;%grp%;%ghrelin%;%ghrh%;%ghrf%;%gip%;%glucagon%;%glp%;%insulin%;%insl3%;%ll37%;%mch%;%motilin%;%npy%;%ofq%;%nociceptin%;%orexina%;%oxytocin%;%pacreaticpolypeptide%;%pyy%;%rbp-4%;%resistin%;%secretin%;%somatostatin%;%substancep%;%tnf-alpha%;%vip%;%urotensinII%;%visfatin%


分类搜索
关键字搜索
按字母搜索
A B C D E F G H I J K L M N
O P Q R S T U V W X Y Z

Copyright 2019 PHOENIX BIOTECH